Get Your Personalized Supplement StackSupplement Stack Quiz

Monoammonium Glycyrrhizinate

Also known as: Monoammonium Glycyrrhizinate, Glycyrrhizic Acid Ammonium Salt

Overview

Monoammonium Glycyrrhizinate is a derivative of glycyrrhizic acid, a compound found in licorice root. It is primarily recognized for its medicinal properties, particularly its anti-inflammatory and hepatoprotective effects. This compound is often utilized in the treatment of liver diseases, aiming to reduce inflammation and support liver function. It has also been explored as an adjunct therapy in chemotherapy to mitigate potential hepatotoxicity. Monoammonium Glycyrrhizinate has a molecular formula of C42H63NO16 and is notable for its water solubility, which facilitates intravenous administration. While research on this compound is ongoing, existing clinical studies suggest promising results in liver protection and inflammation reduction. However, more rigorous trials, including systematic reviews and meta-analyses, are necessary to fully establish its efficacy and safety profile.

Benefits

Monoammonium Glycyrrhizinate has demonstrated potential in improving liver function by reducing liver enzymes, such as ALT and AST, in patients with liver injury. Studies suggest its effectiveness in preventing hepatotoxicity from chemotherapy is less conclusive. Some research indicates anti-inflammatory properties, though further studies are needed to confirm this benefit. It is particularly noted for its potential benefits in patients with liver conditions or those undergoing chemotherapy. Clinical significance varies across studies, with some showing statistically significant improvements in liver function. However, effect sizes are not consistently reported, and the time course of benefits remains to be well-documented.

How it works

Monoammonium Glycyrrhizinate is believed to exert its effects through multiple mechanisms, primarily by inhibiting inflammation and potentially enhancing liver cell regeneration. It interacts primarily with the liver and immune systems. While the exact molecular targets are not fully defined, it is thought to modulate inflammatory pathways. When administered intravenously, it is expected to have high bioavailability due to direct entry into the bloodstream. Further research is needed to fully elucidate the precise mechanisms of action and molecular targets of Monoammonium Glycyrrhizinate.

Side effects

Monoammonium Glycyrrhizinate is generally considered safe when used appropriately, although long-term safety data are limited. Common side effects reported in some cases include nausea and rash. Data on uncommon and rare side effects are limited. Potential interactions with other medications, especially those metabolized by the liver, require further investigation. There are no well-established contraindications, but caution is advised in patients with severe kidney or liver dysfunction. Use in pregnant or breastfeeding women should be approached with caution due to limited data. It is important to monitor patients for any adverse reactions and to consult with a healthcare professional before using Monoammonium Glycyrrhizinate, especially in combination with other medications.

Dosage

The minimum effective dose of Monoammonium Glycyrrhizinate is not well-established, but it is typically used in clinical settings as part of a broader treatment regimen. Clinical studies often involve intravenous administration, but specific optimal ranges are not clearly defined. The maximum safe dose has not been established in the literature. It is often administered in conjunction with other treatments, such as chemotherapy. Intravenous administration is common for clinical use, providing high bioavailability. Due to the lack of established dosage guidelines and potential for interactions, it is crucial to use Monoammonium Glycyrrhizinate under the supervision of a healthcare professional.

FAQs

How is Monoammonium Glycyrrhizinate typically used?

It is typically used in a clinical setting due to its intravenous administration, often as part of a treatment regimen for liver conditions or to mitigate chemotherapy-induced hepatotoxicity.

Is Monoammonium Glycyrrhizinate safe?

While generally safe, long-term use and interactions with other medications require further study. It's important to consult with a healthcare professional before use.

What are the expected results from using Monoammonium Glycyrrhizinate?

The expected results include improvement in liver function and reduction in inflammation, particularly in patients with liver conditions or those undergoing chemotherapy.

Can Monoammonium Glycyrrhizinate replace standard medical treatments?

No, it is not a substitute for standard medical treatment but rather an adjunctive therapy used to support liver function and reduce inflammation.

Research Sources

https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1003697/full – This systematic review of 598 patients with COVID-19, including those with liver injury, found that glycyrrhizic acid preparations, including monoammonium glycyrrhizinate, show promise in improving liver function. The review acknowledges limitations due to variability in study design and outcomes, indicating a moderate quality of evidence.
https://ar.iiarjournals.org/content/anticanres/41/12/6231.full.pdf – A clinical study involving 118 children and adolescents with acute leukemia examined the impact of monoammonium glycyrrhizinate during the first week of induction therapy. The study concluded that monoammonium glycyrrhizinate did not significantly prevent hepatotoxicity from methotrexate-containing chemotherapy, with the study design being retrospective and having a limited sample size.